Department of Brain Health News
The department of brain health is dedicated to advancing research, education, and clinical care to benefit brain health and the care and treatment of people with brain disorders across the lifespan. The faculty specializes in several areas that range from basic to clinical research in neurodegenerative disease and stroke.
Current Brain Health News
UNLV boasts Nevada’s only MRI facility dedicated to university research. Here’s what our professors hope to discover with it.
A collection of top headlines featuring UNLV faculty and students.
Tenth annual report led by noted clinician-scientist Dr. Jeffrey Cummings tracks status, trends associated with 192 active clinical trials worldwide.
Some of the hottest headlines featuring UNLV faculty, staff, and students.
The top news stories starring university students and staff.
Data provided by UNLV researchers helped secure FDA approval for a new blood test to detect Alzheimer’s disease.
Brain Health In The News
Cutting-edge research involving tiny lab-grown cell clusters known as ‘organoids’ are providing breakthroughs in brain research at UNLV.
Biogen is pushing its experimental Alzheimer’s drug diranersen into Phase 3 trials despite missing the primary dose-response goal in its 416-patient CELIA study, after the lowest tested dose paradoxically delivered the strongest results—slowing cognitive decline on the CDR-SB scale by 26% over 18 months.
UNLV researchers are working with former football players and professional fighters to track head injuries and brain damage.
Transferrin Receptor Hijacking Delivers a 1,000-Fold Brain Exposure Leap for Oligonucleotides
The 2026 Alzheimer disease drug development landscape highlights a growing shift toward diverse disease-modifying strategies, from amyloid and tau targeting to metabolic and neuroprotective approaches.
The extended-release oral combination of dextromethorphan-bupropion uses a different mechanism of action than antipsychotic medications, which clinicians sometimes prescribe for patients with Alzheimer's disease who also experience agitation. But whether the new medication will be used as a first-line treatment is up for debate.
